Mr. Sullivan has served as Corporate Controller of Astrotech Corporation, Astrogenetix's parent company, since 2014.
Formed by its parent company, Astrotech Corporation (NASDAQ: ASTC) (formerly SPACEHAB) in 2008, Astrogenetix is one of the first commercial entities to hold a Space Act Agreement (SAA) with NASA for use of the International Space Station – a designated U.S. National Laboratory – for research, development and industrial processing purposes.
An Astrotech Company
Copyright © Astrogenetix Corporation. All rights reserved.
Chief Operating Officer
Mr. Mellacheruvu has served as Vice President and Chief Operating Officer of the Company since 2015.
This Agreement, along with the Company’s relationship with various universities and government agencies and departments, gives Astrogenetix the ability to conduct valuable research and develop products in space to be commercialized on Earth.
Through expertise gained by sending more than 1,500 NASA science experiments into space, Astrogenetix is exclusively positioned to help commercialize products derived from microgravity discoveries. The Company is currently in the process of developing vaccine candidates in microgravity, with a focus on Salmonella and methicillin-resistant Staphylococcus aureus (MRSA).
Thomas B. Pickens III
Founder & CEO
Mr. Pickens has served as a Director since 2004, and as CEO of Astrogenetix's parent company, Astrotech Corporation, since 2007.
Astrogenetix is the first biotech company to research and develop novel therapeutic products in the unique environment of microgravity in space.
Eric N. Stober
Chief Financial Officer
Mr. Stober has served as the Chief Financial Officer, Treasurer and Secretary of the Company since 2013.